ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 42 | November 1, 1985

Download PDF Visit The Full Archive

Related Articles

Senate Raises Funding For Cervical, Ovarian, Prostate Cancer

September 18, 1992

Age Doesn’t Affect Survival After Bone Marrow Transplant

December 26, 2008

Mass. Law Requires Reimbursement For Off-Label Cancer Drugs

January 22, 1993

Patient Advocacy: Prostate Cancer Agenda Didn’t Include NCI Plans, Lausner Says

November 29, 1996

IARC Says Evidence Supports Mammography Screening For 50-69, Limited Evidence For 40-49

March 22, 2002

Two Studies Demonstrate Molecule Blocking Cell Damage

August 26, 2011